Efficacy and safety of burosumab compared with conventional therapy in patients with X-linked hypophosphatemia: A systematic review

ABSTRACT Burosumab, a monoclonal antibody directed against the fibroblast growth factor 23 (FGF23), has been approved for the treatment of X-linked hypophosphatemia (XLH). We conducted a systematic review to compare the efficacy and safety of burosumab versus conventional therapy (phosphorus and cal...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Manjunath Havalappa Dodamani, Samantha Cheryl Kumar, Samiksha Bhattacharjee, Rohit Barnabas, Sandeep Kumar, Anurag Ranjan Lila, Saba Samad Memon, Manjiri Karlekar, Virendra A. Patil, Tushar R. Bandgar
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Sociedade Brasileira de Endocrinologia e Metabologia 2024-06-01
Cyfres:	Archives of Endocrinology and Metabolism
Pynciau:	Burosumab calcitriol phosphorus X-linked hypophosphatemia
Mynediad Ar-lein:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972024000100707&tlng=en
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!